Oramed Pharmaceuticals
ORMP
116 hedge funds and large institutions have $122M invested in Oramed Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 44 increasing their positions, 15 reducing their positions, and 13 closing their positions.
193% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 15
177% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 13
125% more call options, than puts
Call options by funds: $5.67M | Put options by funds: $2.52M
25% more funds holding
Funds holding: 93 → 116 (+23)
5.87% more ownership
Funds ownership: 16.65% → 22.52% (+5.9%)
3% more capital invested
Capital invested by funds: $119M → $122M (+$3.34M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$14.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$10.8M |
| 3 |
Two Sigma Investments
New York
|
+$8.41M |
| 4 |
Morgan Stanley
New York
|
+$5.57M |
| 5 |
Two Sigma Advisers
New York
|
+$4.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$15.5M |
| 2 |
JC
Jetstream Capital
Brentwood,
Tennessee
|
-$2.64M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.46M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$887K |
| 5 |
Man Group
London,
United Kingdom
|
-$820K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Koshinski Asset Management
Decatur,
Illinois
| – | -$9.67K | -440 | Closed |
|
|
MAM
127
Meeder Asset Management
Dublin,
Ohio
| – | -$3K | -95 | Closed |
|
|
EI
128
Ellevest Inc
New York
| – | +$460 | +22 | New |
|
ORMP Hedge Fund Activity: Q4 2021 in Review
116 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2021, worth a combined $122M — up 2.8% from $119M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ORMP positions and 13 closed out — a net gain of 23 holders — while 44 added to existing stakes and 15 trimmed.
The largest buyer was Millennium Management, adding an estimated $14.5M. The largest seller was Invesco, cutting an estimated $15.5M.
- 116 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2021, up from 93 in Q3 2021.
- Funds reported $122M of Oramed Pharmaceuticals stock for Q4 2021, up 2.8% quarter-over-quarter.
- 36 funds opened new Oramed Pharmaceuticals positions in Q4 2021 and 13 closed out, a net change of +23 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2021 was Millennium Management, an estimated $14.5M added.
- The largest Oramed Pharmaceuticals seller in Q4 2021 was Invesco, an estimated $15.5M sold.
Based on aggregated 13F filings for Q4 2021.